Overview

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ticagrelor